• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=29846633; PubMed=30737244).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=29846633; PubMed=30737244).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu326Ter (c.976G>T); ClinVar=VCV000231815; Zygosity=Unspecified (PubMed=29846633; PubMed=30737244).
  

CLPUB00321
Marlow L.A., Rohl S.D., Kennedy G.T., Milosevic D., Grebe S.K.G., Reddi H.V., Eberhardt N.L., Morris J.C., Trujillo M.A., McDonough S.J., McIver B., Bible K.C., Casler J.D., Smallridge R.C., Copland J.A. 3rd
Newly characterized follicular thyroid carcinoma cell lines demonstrate antitumor synergy in response to combined MEK and AKT inhibitors.
(In conference) 82nd annual meeting of the American Thyroid Association; pp.A61-A61; American Thyroid Association; Quebec; Canada (2012)

PubMed=25675381; DOI=10.1210/jc.2014-2764; PMCID=PMC4422887
von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J., Tun H.W., Smallridge R.C., Copland J.A. 3rd
Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
J. Clin. Endocrinol. Metab. 100:E697-E709(2015)

PubMed=29846633; DOI=10.1210/jc.2017-01845; PMCID=PMC6126888
Marlow L.A., Rohl S.D., Miller J.L., Knauf J.A., Fagin J.A., Ryder M., Milosevic D., Netzel B.C., Grebe S.K.G., Reddi H.V., Smallridge R.C., Copland J.A. 3rd
Methodology, criteria, and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts.
J. Clin. Endocrinol. Metab. 103:3169-3182(2018)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)